Analytical Method Development for 19 Alkyl Halides as Potential Genotoxic Impurities by Analytical Quality by Design

Area of Science:

• Pharmaceutical analysis
• Analytical chemistry
• Impurity profiling

Background:

• Efficient risk management of potential genotoxic impurities (PGIs) is a major challenge in the pharmaceutical industry.
• Developing sensitive analytical methods is crucial for controlling PGIs and ensuring drug safety.
• Limited studies have explored the analytical Quality by Design (QbD) approach for PGI method development using GC-MS.

Purpose of the Study:

• To develop a sensitive and simultaneous analytical method for controlling 19 specific alkyl halides identified as PGIs.
• To apply the analytical Quality by Design (QbD) approach for robust PGI method development.
• To establish a validated GC-MS method for PGI analysis in pharmaceutical products.

Main Methods:

• Selection of 19 alkyl halides as PGIs from 144 candidates using in silico quantitative structure-activity relationship (Q-SAR) studies.
• Development of a sensitive analytical method using gas chromatography with a mass spectrometry detector (GC-MS).
• Validation of the GC-MS method according to ICH Q2 guidelines, assessing specificity, LOD, LOQ, linearity, accuracy, and precision.

Main Results:

• An optimally sensitive and simultaneous GC-MS method was successfully developed for 19 alkyl halide PGIs.
• The analytical QbD approach ensured the development of a robust and sensitive method for PGI control.
• The method demonstrated acceptable validation parameters, meeting ICH Q2 guideline requirements.

Conclusions:

• The developed GC-MS method provides an effective tool for the sensitive and simultaneous detection of 19 alkyl halide PGIs.
• The application of the analytical QbD approach enhances the reliability and robustness of PGI analysis.
• This validated method contributes to improved risk management and control strategies for PGIs in the pharmaceutical industry.